![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, November 18, 2017 2:30:12 PM
Simple logic is FDA could be THE leader in preventing many tens of thousands of those in pain from becoming addicts by simply issuing both back and general OTC clearance for ActiPatch - I realize the redundancy but they should issue both clearances as back clearance efforts are underway and general clearance should automatically and immediately follow.
Given that FDA has already approved RecoveryRx for post-op eye surgeries and OTC clearances for foot and knee pain, and all dem bones is connected to all dem other bones, am I being too logical? With the absurd lack of common sense of ActiPatch being partially cleared and not fully, hope it is clear why I was shaking my head at the Rx approval of a questionalable device for addiction withdrawal symptoms. Good luck to the owners of that IP, but it makes zero sense that FDA is delaying ActiPatc clearance for one day longer. The ultimate mission is to prevent misuse, abuse and addiction to pain drugs in the first place!
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM